Considering Syneos Health Inc. (SYNH) as a potential investment: What Should You Do?

The price of Syneos Health Inc. (NASDAQ: SYNH) closed at $34.60 in the last session, down -0.57% from day before closing price of $34.80. In other words, the price has decreased by -$0.20 from its previous closing price. On the day, 1262951 shares were traded. SYNH stock price reached its highest trading level at $34.78 during the session, while it also had its lowest trading level at $33.84.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…



We take a closer look at SYNH’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 20.67 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.96. For the most recent quarter (mrq), Quick Ratio is recorded 1.10 and its Current Ratio is at 1.10. In the meantime, Its Debt-to-Equity ratio is 0.84 whereas as Long-Term Debt/Eq ratio is at 0.84.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Barclays on January 17, 2023, Downgraded its rating to Underweight and sets its target price to $25 from $30 previously.

On January 13, 2023, Barclays Downgraded its rating to Underweight which previously was Overweight but kept the price unchanged to $25.

Mizuho Downgraded its Buy to Neutral on December 14, 2022, whereas the target price for the stock was revised from $66 to $38.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jul 28 when Brooks Michael Lee sold 500 shares for $78.00 per share. The transaction valued at 39,000 led to the insider holds 9,342 shares of the business.

Brooks Michael Lee sold 1,002 shares of SYNH for $78,156 on Jul 28. The Chief Operating Officer now owns 47,552 shares after completing the transaction at $78.00 per share. On Jul 21, another insider, Brooks Michael Lee, who serves as the Chief Operating Officer of the company, sold 500 shares for $76.00 each. As a result, the insider received 38,000 and left with 9,842 shares of the company.

Valuation Measures:

As of this moment, Syneos’s Price-to-Earnings (P/E) ratio for their current fiscal year is 12.52, and their Forward P/E ratio for the next fiscal year is 8.72. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.40. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.65 while its Price-to-Book (P/B) ratio in mrq is 1.06.

Stock Price History:

Over the past 52 weeks, SYNH has reached a high of $92.62, while it has fallen to a 52-week low of $22.89. The 50-Day Moving Average of the stock is 34.20, while the 200-Day Moving Average is calculated to be 57.72.

Shares Statistics:

According to the various share statistics, SYNH traded on average about 1.70M shares per day over the past 3-months and 2.22M shares per day over the past 10 days. A total of 102.73M shares are outstanding, with a floating share count of 61.25M. Insiders hold about 0.20% of the company’s shares, while institutions hold 99.30% stake in the company. Shares short for SYNH as of Oct 13, 2022 were 1.67M with a Short Ratio of 6.06M, compared to 1.66M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 1.63% and a Short% of Float of 1.63%.

Earnings Estimates

The company has 10 analysts who recommend its stock at the moment. On average, analysts expect EPS of $1.32 for the current quarter, with a high estimate of $1.34 and a low estimate of $1.24, while EPS last year was $1.22. The consensus estimate for the next quarter is $1.39, with high estimates of $1.47 and low estimates of $1.34.

Analysts are recommending an EPS of between $5.05 and $4.84 for the fiscal current year, implying an average EPS of $4.98. EPS for the following year is $5.18, with 12 analysts recommending between $5.39 and $4.61.

Revenue Estimates

According to 11 analysts, the current quarter’s revenue is expected to be $1.37B. It ranges from a high estimate of $1.42B to a low estimate of $1.36B. As of the current estimate, Syneos Health Inc.’s year-ago sales were $1.35B, an estimated increase of 1.90% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $1.4B, an increase of 1.60% less than the figure of $1.90% in the same quarter last year. There is a high estimate of $1.44B for the next quarter, whereas the lowest estimate is $1.37B.

A total of 13 analysts have provided revenue estimates for SYNH’s current fiscal year. The highest revenue estimate was $5.56B, while the lowest revenue estimate was $5.43B, resulting in an average revenue estimate of $5.47B. In the same quarter a year ago, actual revenue was $5.21B, up 4.90% from the average estimate. Based on 13 analysts’ estimates, the company’s revenue will be $5.7B in the next fiscal year. The high estimate is $6.01B and the low estimate is $5.41B. The average revenue growth estimate for next year is up 4.30% from the average revenue estimate for this year.